


What is claimed is:

1. A compound of Formula I or a pharmaceutically acceptable salt thereof:



5

I

wherein

- $R^1$  is selected from  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $R^5-C(=O)-O-$   
 $C_{1-6}$ alkyl,  $R^5R^6N-C_{1-6}$ alkyl,  $R^5O-C_{1-6}$ alkyl,  $R^5C(=O)N(-R^6)-C_{1-6}$ alkyl,  $R^5R^6NS(=O)_2-$   
 $C_{1-6}$ alkyl,  $R^5CS(=O)_2N(-R^6)-C_{1-6}$ alkyl,  $R^5R^6NC(=O)N(-R^7)-C_{1-6}$ alkyl,  
 10  $R^5R^6NS(=O)_2N(R^7)-C_{1-6}$ alkyl,  $C_{6-10}$ aryl- $C_{1-6}$ alkyl,  $C_{6-10}$ aryl- $C(=O)-C_{1-6}$ alkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocyclyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocyclyl- $C(=O)-C_{1-6}$ alkyl,  $C_{1-10}$ hydrocarbylamino,  $R^5R^6N-$ ,  $R^5O-$ ,  $R^5C(=O)N(-R^6)-$ ,  $R^5R^6NS(=O)_2-$ ,  $R^5CS(=O)_2N(-R^6)-$ ,  $R^5R^6NC(=O)N(-R^7)-$ ,  $R^5R^6NS(=O)_2N(R^7)-$ ,  
 $C_{6-10}$ aryl,  $C_{6-10}$ aryl- $C(=O)-$ ,  $C_{3-10}$ cycloalkyl,  $C_{4-8}$ cycloalkenyl,  $C_{3-6}$ heterocyclyl and  $C_{3-6}$ heterocyclyl- $C(=O)-$ ; wherein said  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{6-10}$ aryl- $C_{1-6}$ alkyl,  $C_{6-10}$ aryl- $C(=O)-C_{1-6}$ alkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocyclyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocyclyl- $C(=O)-C_{1-6}$ alkyl,  $C_{1-10}$ hydrocarbylamino,  $C_{6-10}$ aryl,  $C_{6-10}$ aryl- $C(=O)-$ ,  $C_{3-10}$ cycloalkyl,  $C_{4-8}$ cycloalkenyl,  $C_{3-6}$ heterocyclyl or  $C_{3-6}$ heterocyclyl- $C(=O)-$  used in defining  $R^1$  is optionally substituted  
 15 by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and  $-NR^5R^6$ ;


- $R^2$  is selected from  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-10}$ cycloalkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl,  $R^5R^6N-$ ,  $C_{3-5}$ heteroaryl,  $C_{6-10}$ aryl and  $C_{3-6}$ heterocycloalkyl, wherein  
 25 said  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl,  $C_{3-5}$ heteroaryl,  $C_{6-10}$ aryl or  $C_{3-6}$ heterocycloalkyl used in defining  $R^2$  is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and  $-NR^5R^6$ ;

wherein  $R^5$ ,  $R^6$  and  $R^7$  are independently selected from  $-H$ ,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, and a divalent  $C_{1-6}$ group that together with another divalent  $R^5$ ,  $R^6$  or  $R^7$  forms a portion of a ring;


Ar is selected from  $C_{6-10}$ aryl and  $C_{3-8}$ heteroaryl;

5 n is selected from 0, 1, 2 and 3;

each of  $R^3$  is independently selected from  $-H$ , nitro, halogen,  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-10}$ cycloalkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{4-8}$ cycloalkenyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocycloalkyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocycloalkyl and



10 optionally substituted with one or more groups selected from  $C_{1-6}$ alkyl, hydroxy, halogen, amino and  $C_{1-6}$ alkoxy,



each of R<sup>8</sup> and R<sup>9</sup> is independently selected from -H, C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-10</sub>cycloalkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-6</sub>alkyl, C<sub>3-6</sub>heterocyclyl, C<sub>6-10</sub>aryl, C<sub>3-6</sub>heterocyclyl-C<sub>1-6</sub>alkyl, C<sub>6-10</sub>aryl-C<sub>1-6</sub>alkyl, and a divalent C<sub>1-6</sub>group that together with another divalent group selected from R<sup>8</sup> and R<sup>9</sup> forms a portion of a ring, wherein said C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-10</sub>cycloalkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-6</sub>alkyl, C<sub>3-6</sub>heterocyclyl, C<sub>6-10</sub>aryl, C<sub>3-6</sub>heterocyclyl-C<sub>1-6</sub>alkyl, C<sub>6-10</sub>aryl-C<sub>1-6</sub>alkyl, or divalent C<sub>1-6</sub>group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR<sup>5</sup>R<sup>6</sup>; and

R<sup>4</sup> is selected from -H, C<sub>1-10</sub>alkyl, C<sub>2-10</sub>alkenyl, C<sub>2-10</sub>alkynyl, C<sub>3-10</sub>cycloalkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-6</sub>alkyl, and C<sub>4-8</sub>cycloalkenyl-C<sub>1-6</sub>alkyl.

2. A compound as claimed in claim 1, wherein

R<sup>1</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-C(=O)-O-C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, phenyl-C<sub>1-4</sub>alkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocyclyl-C<sub>1-4</sub>alkyl, C<sub>6-10</sub>aryl, C<sub>3-6</sub>heterocyclyl, C<sub>3-10</sub>cycloalkyl, and C<sub>4-6</sub>cycloalkenyl, wherein said C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-C(=O)-O-C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, phenyl-C<sub>1-4</sub>alkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocyclyl-C<sub>1-4</sub>alkyl, C<sub>6-10</sub>aryl, C<sub>3-6</sub>heterocyclyl, C<sub>3-10</sub>cycloalkyl, and C<sub>4-6</sub>cycloalkenyl are defined as above.

alkynyl, phenyl-C<sub>1-4</sub>alkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>6-10</sub>aryl, C<sub>3-6</sub>heterocyclyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocyclyl, C<sub>3-10</sub>cycloalkyl, and C<sub>4-6</sub>cycloalkenyl used in defining R<sup>1</sup> is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and -NR<sup>5</sup>R<sup>6</sup>;

R<sup>2</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl, C<sub>3-5</sub>heteroaryl, R<sup>5</sup>R<sup>6</sup>N-, and phenyl, wherein said C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl, C<sub>3-5</sub>heteroaryl, R<sup>5</sup>R<sup>6</sup>N-, and phenyl used in defining R<sup>2</sup> is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;


wherein R<sup>5</sup> and R<sup>6</sup> are independently selected from -H, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, and a divalent C<sub>1-6</sub>alkylene that together with another divalent R<sup>5</sup> or R<sup>6</sup> and optionally a heteroatom forms a portion of a ring;

Ar is selected from phenyl and C<sub>3-5</sub>heteroaryl;


n is selected from 0, 1 and 2;

each of R<sup>3</sup> is independently selected from -H, nitro, halogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>heterocycloalkyl-C<sub>1-4</sub>alkyl,

20



and, C<sub>3-6</sub>heterocycloalkyl optionally substituted with one or more groups selected from C<sub>1-6</sub>alkyl, hydroxy, halogen and




- each of R<sup>8</sup> and R<sup>9</sup> is independently selected from -H, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-6</sub>alkyl, C<sub>3-6</sub>heterocyclyl and C<sub>3-6</sub>heterocyclyl-C<sub>1-6</sub>alkyl, wherein said C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl-C<sub>1-6</sub>alkyl, C<sub>3-6</sub>heterocyclyl and C<sub>3-6</sub>heterocyclyl-C<sub>1-6</sub>alkyl are optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR<sup>10</sup>R<sup>11</sup>; and

R<sup>4</sup>, R<sup>10</sup> and R<sup>11</sup> are independently selected from -H and C<sub>1-3</sub>alkyl.

3. A compound as claimed claim 1,  
 wherein R<sup>1</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>1-3</sub>alkyl-C(=O)-O-C<sub>1-3</sub>alkyl, C<sub>2-6</sub>alkenyl, phenyl-C<sub>1-4</sub>alkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocyclcoalkyl-C<sub>1-4</sub>alkyl, C<sub>6-10</sub>aryl, C<sub>3-10</sub>cycloalkyl, and C<sub>4-6</sub>cycloalkenyl, wherein said C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, phenyl-C<sub>1-4</sub>alkyl, C<sub>3-10</sub>cycloalkyl-C<sub>1-4</sub>alkyl, C<sub>4-6</sub>cycloalkenyl-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>heterocyclcoalkyl-C<sub>1-4</sub>alkyl, C<sub>6-10</sub>aryl, C<sub>3-10</sub>cycloalkyl, and C<sub>4-6</sub>cycloalkenyl used in defining R<sup>1</sup> is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and amino;
- R<sup>2</sup> is selected from C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl, wherein said C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>3-6</sub>cycloalkyl and C<sub>3-6</sub>cycloalkyl-C<sub>1-4</sub>alkyl used in defining R<sup>2</sup> is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
- Ar is selected from phenyl and C<sub>3-5</sub>heteroaryl and
- n is selected from 0, 1 and 2;

each of  $R^3$  is independently selected from  $-H$ , halogen, nitro,  $C_{1-3}$ alkyl,  $C_{3-6}$ heterocycloalkyl



wherein said  $C_{3-6}$ heterocycloalkyl contain at least one nitrogen ring atom and the radical of  $C_{3-6}$ heterocycloalkyl is located on the at least one nitrogen ring atom, and wherein each of  $R^8$  and  $R^9$  is independently selected from  $-H$ ,  $C_{1-6}$ alkyl, morpholinyl- $C_{1-3}$ alkyl, pyrrolidinyl- $C_{1-3}$ alkyl, and piperidinyl- $C_{1-3}$ alkyl, wherein said  $C_{1-6}$ alkyl, morpholinyl- $C_{1-3}$ alkyl, pyrrolidinyl- $C_{1-3}$ alkyl, and piperidinyl- $C_{1-3}$ alkyl are optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy and  $-NR^5R^6$ ; and

$R^4$ ,  $R^5$  and  $R^6$  are independently selected from  $-H$  and  $C_{1-3}$ alkyl.

4. A compound as claimed in claim 1, wherein


$R^1$  is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, cyclohexylethyl, cyclopentylethyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, 4,4-difluorocyclohexylmethyl, tetrahydropyranylmethyl, tetrahydropyranylethyl, tetrahydrofuranylmethyl, 1-piperidinyloethyl, and N-methyl-2-piperidinylmethyl;

$R^2$  is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxyl-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

Ar is selected from phenyl, pyridyl, pyrimidyl, thiazolyl, thienyl, isoxazolyl, imidazolyl, and pyrazolyl;

n is selected from 0, 1 and 2;

each of  $R^3$  is independently selected from  $-H$ ,  $C_{1-3}$ alkyl, 4-morpholinyl, 1-



wherein 4-morpholinyl, 1-piperidinyl, and 1-piperazinyl are optionally substituted with one or more methyl; and wherein

- each of R<sup>8</sup> and R<sup>9</sup> is independently selected from -H, C<sub>1-3</sub>alkyl, morpholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl, wherein said
- 5 C<sub>1-3</sub>alkyl, morpholinylmethyl, pyrrolidinyl-methyl, and piperidinyl-methyl are optionally substituted by one or more groups selected from hydroxy, amino and dimethylamino.

5. A compound selected from:

- 10 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]thiophene-2-sulfonamide;
- N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylthiophene-2-sulfonamide;
- N*-(1-Benzyl-2-*tert*-butyl-1*H*-benzimidazol-5-yl)-*N*-methylbenzenesulfonamide;
- 15 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,3,5-trimethylisoxazole-4-sulfonamide;
- N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,1,2-trimethyl-1*H*-imidazole-4-sulfonamide;
- N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,1,3,5-
- 20 tetramethyl-1*H*-pyrazole-4-sulfonamide;
- N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]benzene sulphonamide;
- N*-[1-(cyclohexylmethyl)-2-ethyl-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-isopropyl-1*H*-benzimidazol-5-yl]benzene
- 25 sulphonamide;
- N*-[1-(cyclohexylmethyl)-2-(1-methylcyclopropyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- 30 *N*-[1-(cyclohexylmethyl)-2-(1,1-dimethyl-3-butenyl)-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-(1-methyl-4-piperidinyl)-1*H*-benzimidazol-5-yl]-benzenesulfonamide;

- N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-ethyl-1*H*-benzimidazol-5-yl]-*N*-methyl-benzene sulphonamide;
- 5 *N*-[1-(cyclohexylmethyl)-2-isopropyl-1*H*-benzimidazol-5-yl]-*N*-methyl-benzene sulphonamide;
- N*-[1-(cyclohexylmethyl)-2-(1-methylcyclopropyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-(1-methyl-4-piperidiny)-1*H*-benzimidazol-5-yl]-*N*-methyl- benzenesulfonamide;
- 10 4-[1-(cyclohexylmethyl)-5-[methyl(phenylsulfonyl)amino]-1*H*-benzimidazol-2-yl]-1,1-dimethyl- piperidinium;
- N*-[2-(1,1-dimethylethyl)-1-[(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- 15 *N*-[2-(1,1-dimethylethyl)-1-[(tetrahydro-2-furanyl)methyl]-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- N*-[1-(cyclobutylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- N*-[1-(cyclopropylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- 20 *N*-(4-{[[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide;
- N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-6-morpholin-4-ylpyridine-3-sulfonamide;
- 25 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-nitrobenzenesulfonamide;
- 4-Amino-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)propanamide;
- 30 *N*-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-methylpropanamide;

- N*-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;  
*N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(ethylamino)-*N*-methylbenzenesulfonamide;
- 5 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(formylamino)-*N*-methylbenzenesulfonamide;
- 2-Bromo-*N*-(4-{[[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
- N*-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide;
- 10 *N*<sup>1</sup>-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;
- N*-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide;
- 15 *N*<sup>1</sup>-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)glycinamide;
- 2-[(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate;
- N*-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
- 20 *N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-(4-morpholinyl)-benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-(4-methyl-1-piperazinyl)-benzenesulfonamide;
- 25 *N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-2-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-(1-hydroxy-1-methylethyl)-1*H*-benzimidazol-5-yl]-benzenesulfonamide;
- 30 *N*-[1-(cyclohexylmethyl)-2-(1-methoxy-1-methylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-benzenesulfonamide;

- N*-[1-(cyclohexylmethyl)-2-(1-methoxy-1-methylethyl)-1*H*-benzimidazol-5-yl]—benzenesulfonamide;
- N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*,1,2-trimethyl-1*H*-imidazole-5-sulfonamide;
- 5 Ethyl 4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methylamino)sulfonyl}-3,5-dimethyl-1*H*-pyrrole-2-carboxylate;
- N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-(hydroxymethyl)-*N*-methylbenzenesulfonamide;
- N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-(1*H*-1,2,3-triazol-1-ylmethyl)benzenesulfonamide;
- 10 *N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-[[2-(hydroxyethyl)amino]methyl]-*N*-methylbenzenesulfonamide;
- N*-[2-*tert*-Butyl-1-(cyclopentylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- 15 *N*-[2-*tert*-Butyl-1-(2-cyclohexylethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-[1-(1-Benzylpyrrolidin-3-yl)-2-*tert*-butyl-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-{2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}-*N*-methylbenzenesulfonamide;
- 20 *N*-[2-*tert*-Butyl-1-(pyridin-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- 25 *N*-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(2,2,2-trifluoroethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- N*-[1-(cyclohexylmethyl)-2-(1-ethylpropyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- 30 *N*-[1-(cyclohexylmethyl)-2-(1-ethylpropyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide; *N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;

*N*-methyl-*N*-[2-(1-methyl-1-pyridin-2-ylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;

*N*-[2-(1-cyano-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

5 *N*-methyl-*N*-[2-propyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;

5-Bromo-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-chloro-*N*-methylpyridine-3-sulfonamide;

5-Bromo-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;

10 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;

*N*-(5-[[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide;

15 *N*-(3-[[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

*N*<sup>1</sup>-(4-[[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*<sup>2</sup>-(2-hydroxyethyl)glycinamide;

4-[(Aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

20 *N*-(4-[[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

*N*-(4-[[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*-methylacetamide;

25 *N*-(4-[[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;

*N*-(4-[[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;

30 *N*<sup>1</sup>-(4-[[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*<sup>2</sup>,*N*<sup>2</sup>-dimethylglycinamide;

*N*<sup>1</sup>-(4-[[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)glycinamide;

- N*<sup>1</sup>-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*<sup>2</sup>-methylglycinamide;
- N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;
- 5 *N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-methoxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;
- N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-(formylamino)-*N*-methylpyridine-3-sulfonamide;
- N*-(5-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide;
- 10 *N*-[4-({[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
- N*-[4-({[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
- 15 *N*-(4-{[[2-*tert*-Butyl-1-(2-piperidin-1-ylethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
- N*-(4-{[[2-*tert*-Butyl-1-(1,4-dioxan-2-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
- N*-(4-{[2-*tert*-Butyl-1-[(1-methylpiperidin-2-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
- 20 *N*-(4-{[2-*tert*-Butyl-1-[(2*R*)-1-methylpiperidin-2-yl]methyl]-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
- N*-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
- 25 4-Bromo-*N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-benzenesulfonamide;
- N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-[(2-hydroxyethyl)amino]-*N*-methylbenzenesulfonamide;
- N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(dimethylamino)-*N*-methylbenzenesulfonamide;
- 30 4-[bis(2-hydroxyethyl)amino]-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

- N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,4-dimethyl-3,4-dihydro-2*H*-1,4-benzoxazine-7-sulfonamide;
- N*-[4-({methyl[2-(1-methyl-1-pyridin-2-ylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
- 5 *N*-(4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl}phenyl)acetamide;
- 4-[(aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;
- N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethyl-4-{{[(methylamino)carbonyl]amino}benzenesulfonamide};
- 10 4-amino-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;
- N*-(4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl}phenyl)-2,2-dimethylpropanamide;
- 15 2-[(4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl}phenyl)amino]-2-oxoethyl acetate;
- N*-(4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl}phenyl)-2-hydroxyacetamide;
- N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethyl-4-{{[(isopropylamino)carbonyl]amino}benzenesulfonamide};
- 20 *N*-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
- 4-[(aminocarbonyl)amino]-*N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- 25 *N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-{{[(methylamino)carbonyl]amino}benzenesulfonamide};
- 4-amino-*N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- N*-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]-2,2-dimethylpropanamide;
- 30 2-{{[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate;

- N*-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl]amino)sulfonyl]phenyl]-2-hydroxyacetamide;
- N*-ethyl-4-{{(isopropylamino)carbonyl}amino}-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl]benzenesulfonamide;
- 5 *N*-(4-{{[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide;
- 4-[(aminocarbonyl)amino]-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- 2-Hydroxy-*N*-(4-{{[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide;
- 10 *N*-(4-{{[2-(1-ethoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide;
- N*-[4-({[1-(2-azetidin-1-ylethyl)-2-*tert*-butyl-1*H*-benzimidazol-5-yl]amino)sulfonyl]phenyl]acetamide;
- 15 3-[5-({[4-(acetyl amino)phenyl]sulfonyl}amino)-2-*tert*-butyl-1*H*-benzimidazol-1-yl]propyl acetate;
- N*-{4-[(1-[(1*S*,4*S*)-bicyclo[2.2.1]hept-5-en-2-yl)methyl]-2-*tert*-butyl-1*H*-benzimidazol-5-yl]amino)sulfonyl}phenyl}acetamide;
- N*-[4-({[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-3-yl)methyl]-1*H*-benzimidazol-5-yl]amino)sulfonyl]phenyl]acetamide;
- 20 *N*-{4-[(2-*tert*-butyl-1-[2-(tetrahydro-2*H*-pyran-4-yl)ethyl]-1*H*-benzimidazol-5-yl]amino)sulfonyl}phenyl}acetamide;
- N*-(4-{{[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide;
- 25 4-[(aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
- N*-(4-{{[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2,2-dimethylpropanamide;
- N*-(4-{{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)-2-hydroxyacetamide;
- 30 *N*-(4-{{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl}phenyl)acetamide;

- N*-(4-{[[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-3-methylbutanamide;  
*N*-(4-{[[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;  
 5 *N*-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-{[(isopropylamino)carbonyl]amino}-*N*-methylbenzenesulfonamide;  
 4-{Bis{[(isopropylamino)carbonyl]amino}-*N*-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;  
*N*-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;  
 10 4-[(aminocarbonyl)amino]-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;  
*N*-methyl-4-nitro-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;  
 15 4-amino-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;  
 2,2-dimethyl-*N*-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]propanamide;  
 2-{{4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate;  
 20 4-{[(isopropylamino)carbonyl]amino}-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;  
 2-Hydroxy-*N*-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide  
 25 and pharmaceutically acceptable salts thereof.


6. A compound according to any one of claims 1-5 for use as a medicament.
7. The use of a compound according to any one of claims 1-5 in the manufacture  
 30 of a medicament for the therapy of pain.
8. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of anxiety disorders.

9. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, cancer, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders.

10. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.

10 11. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.


12. A method for preparing a compound of Formula I,



15

I

comprising the step of reacting a compound of Formula II,

II

20 with a compound of  $\text{R}^2\text{C}(=\text{O})\text{X}$ , in the presence of a base and optionally a coupling reagent, followed by treatment with an acid;

wherein

X is selected from Cl, Br, F and OH;

25  $\text{R}^1$  is selected from  $\text{C}_{1-10}$ alkyl,  $\text{C}_{2-10}$ alkenyl,  $\text{C}_{2-10}$ alkynyl,  $\text{R}^5\text{-C}(=\text{O})\text{-O-}$   
 $\text{C}_{1-6}$ alkyl,  $\text{R}^5\text{R}^6\text{N-C}_{1-6}$ alkyl,  $\text{R}^5\text{O-C}_{1-6}$ alkyl,  $\text{R}^5\text{C}(=\text{O})\text{N}(\text{-R}^6)\text{-C}_{1-6}$ alkyl,  $\text{R}^5\text{R}^6\text{NS}(=\text{O})_2\text{-C}_{1-6}$ alkyl,  $\text{R}^5\text{CS}(=\text{O})_2\text{N}(\text{-R}^6)\text{-C}_{1-6}$ alkyl,  $\text{R}^5\text{R}^6\text{NC}(=\text{O})\text{N}(\text{-R}^7)\text{-C}_{1-6}$ alkyl,

$R^5R^6NS(=O)_2N(R^7)-C_{1-6}alkyl$ ,  $C_{6-10}aryl-C_{1-6}alkyl$ ,  $C_{6-10}aryl-C(=O)-C_{1-6}alkyl$ ,  $C_{3-10}cycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocyclyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocyclyl-C(=O)-C_{1-6}alkyl$ ,  $C_{1-10}hydrocarbylamino$ ,  $R^5R^6N-$ ,  $R^5O-$ ,  $R^5C(=O)N(-R^6)-$ ,  $R^5R^6NS(=O)_2-$ ,  $R^5CS(=O)_2N(-R^6)-$ ,  $R^5R^6NC(=O)N(-R^7)-$ ,  $R^5R^6NS(=O)_2N(R^7)-$ ,  
 5  $C_{6-10}aryl$ ,  $C_{6-10}aryl-C(=O)-$ ,  $C_{3-10}cycloalkyl$ ,  $C_{4-8}cycloalkenyl$ ,  $C_{3-6}heterocyclyl$  and  $C_{3-6}heterocyclyl-C(=O)-$ ; wherein said  $C_{1-10}alkyl$ ,  $C_{2-10}alkenyl$ ,  $C_{2-10}alkynyl$ ,  $C_{6-10}aryl-C_{1-6}alkyl$ ,  $C_{6-10}aryl-C(=O)-C_{1-6}alkyl$ ,  $C_{3-10}cycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocyclyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocyclyl-C(=O)-C_{1-6}alkyl$ ,  $C_{1-10}hydrocarbylamino$ ,  $C_{6-10}aryl$ ,  $C_{6-10}aryl-C(=O)-$ ,  $C_{3-10}cycloalkyl$ ,  $C_{4-8}cycloalkenyl$ ,  $C_{3-6}heterocyclyl$  or  $C_{3-6}heterocyclyl-C(=O)-$  used in defining  $R^1$  is optionally substituted  
 10 by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, benzyl, and  $-NR^5R^6$ ;


$R^2$  is selected from  $C_{1-10}alkyl$ ,  $C_{2-10}alkenyl$ ,  $C_{2-10}alkynyl$ ,  $C_{3-10}cycloalkyl$ ,  $C_{3-10}cycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl$ ,  $R^5R^6N-$ ,  $C_{3-5}heteroaryl$ ,  $C_{6-10}aryl$  and  $C_{3-6}heterocycloalkyl$ , wherein  
 15 said  $C_{1-10}alkyl$ ,  $C_{2-10}alkenyl$ ,  $C_{2-10}alkynyl$ ,  $C_{3-8}cycloalkyl$ ,  $C_{3-8}cycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl$ ,  $C_{3-5}heteroaryl$ ,  $C_{6-10}aryl$  or  $C_{3-6}heterocycloalkyl$  used in defining  $R^2$  is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy,  
 20 ethoxy, methyl, ethyl, hydroxy, and  $-NR^5R^6$ ;

wherein  $R^5$ ,  $R^6$  and  $R^7$  are independently selected from  $-H$ ,  $C_{1-6}alkyl$ ,  $C_{2-6}alkenyl$ ,  $C_{2-6}alkynyl$ , and a divalent  $C_{1-6}$  group that together with another divalent  $R^5$ ,  $R^6$  or  $R^7$  forms a portion of a ring;


Ar is selected from  $C_{6-10}aryl$  and  $C_{3-8}heteroaryl$ ;

25 n is selected from 0, 1, 2 and 3;

each of  $R^3$  is independently selected from  $-H$ , nitro, halogen,  $C_{1-10}alkyl$ ,  $C_{2-10}alkenyl$ ,  $C_{2-10}alkynyl$ ,  $C_{3-10}cycloalkyl$ ,  $C_{3-10}cycloalkyl-C_{1-6}alkyl$ ,  $C_{4-8}cycloalkenyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocycloalkyl-C_{1-6}alkyl$ ,  $C_{3-6}heterocycloalkyl$



optionally substituted with one or more groups selected from C<sub>1-6</sub>alkyl, hydroxy, halogen, amino and C<sub>1-6</sub>alkoxy,



- each of  $R^8$  and  $R^9$  is independently selected from  $-H$ ,  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-10}$ cycloalkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocyclyl,  $C_{6-10}$ aryl,  $C_{3-6}$ heterocyclyl- $C_{1-6}$ alkyl,  $C_{6-10}$ aryl- $C_{1-6}$ alkyl, and a divalent  $C_{1-6}$ group that together with another divalent group selected from  $R^8$  and  $R^9$  forms a portion of a ring, wherein said  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-10}$ cycloalkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl,  $C_{3-6}$ heterocyclyl,  $C_{6-10}$ aryl,  $C_{3-6}$ heterocyclyl- $C_{1-6}$ alkyl,  $C_{6-10}$ aryl- $C_{1-6}$ alkyl, or divalent  $C_{1-6}$ group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and  $-NR^5R^6$ ; and
- $R^4$  is selected from  $-H$ ,  $C_{1-10}$ alkyl,  $C_{2-10}$ alkenyl,  $C_{2-10}$ alkynyl,  $C_{3-10}$ cycloalkyl,  $C_{3-10}$ cycloalkyl- $C_{1-6}$ alkyl, and  $C_{4-8}$ cycloalkenyl- $C_{1-6}$ alkyl.